Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EBITDA (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of EBITDA data on record, last reported at -$78.8 million in Q4 2025.

  • For Q4 2025, EBITDA fell 274.63% year-over-year to -$78.8 million; the TTM value through Dec 2025 reached $26.0 million, down 87.36%, while the annual FY2025 figure was $26.0 million, 87.36% down from the prior year.
  • EBITDA reached -$78.8 million in Q4 2025 per AMPH's latest filing, down from $25.3 million in the prior quarter.
  • Across five years, EBITDA topped out at $72.7 million in Q3 2023 and bottomed at -$78.8 million in Q4 2025.
  • Average EBITDA over 5 years is $30.3 million, with a median of $35.2 million recorded in 2023.
  • Peak YoY movement for EBITDA: surged 742.38% in 2021, then tumbled 274.63% in 2025.
  • A 5-year view of EBITDA shows it stood at $24.3 million in 2021, then soared by 56.0% to $37.8 million in 2022, then skyrocketed by 42.68% to $54.0 million in 2023, then dropped by 16.37% to $45.1 million in 2024, then crashed by 274.63% to -$78.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$78.8 million in Q4 2025, $25.3 million in Q3 2025, and $42.2 million in Q2 2025.